Perspective Therapeutics Inc

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q2 2023

Earnings data Q1 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics (CATX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.01 per share a year ago.

Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) --   Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at the University of Wisconsin in the Company's Phase 1/2a dose escalation trial evaluating the safety and efficacy of 212Pb-VMT01 in patients with MC1R+ metastatic melanoma. The trial is a first-in-human, non-randomized, multi-center open-label dose escalation, dose expansion study of 212Pb-VMT01 in patients with histologically confirmed melanoma and a positive MC1R imaging scan.

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced a collaborative initiative focused on increasing access to Cesium-131 brachytherapy for the treatment of certain brain cancers in the form of GT Medical Technologies, Inc.'s (“GT MedTech”) GammaTile Therapy.

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment

RICHLAND, WASHINGTON & CORALVILLE, IOWA , June 21, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that it has initiated clinical trial sites and commenced the enrollment period for its 212Pb-labeled therapeutic product candidates, VMT-α-NET and VMT01.

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in two presentations at the meeting Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in two presentations at the meeting

Perspective Therapeutics' Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society's Annual Meeting

LM Funding America

Zhihu

For those who laugh in the face of extreme financial danger, the concept of acquiring the best penny stock to buy now might get the heart racing. Given this category's often rock-bottom share prices, these wildly speculative ideas command much attention.

The Best Penny Stock to Buy Now ZH vs CATX vs LMFA

Three poster presentations from Perspective Therapeutics' scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 2 03Pb manufacturing, and In Vivo Distribution of Recoiled 213Bi from [225Ac]Ac-DOTATATE

Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)

RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports first quarter financial results for the period ended March 31, 2023.

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

RICHLAND, WA & CORALVILLE, IA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the following changes to the Board of Directors: the appointment of Heidi Henson to the Board of Directors and named Audit Committee Chair; taking over from Rob Williamson, III, who will continue to serve as a member of the Committee. Additionally, Michael McCormick announced his resignation and amicable departure from the Board of Directors

Perspective Therapeutics Announces Changes to the Board of Directors

BOCA RATON, Fla. and RICHLAND, Wash., March 14, 2023 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a contract development and manufacturing organization and radiopharmaceutical manufacturer, today announces the signature of a Master Services Agreement with Viewpoint Molecular Targeting, Inc., a wholly-owned subsidiary of Perspective Therapeutics, Inc. ("Perspective") (NYSE AMERICAN: CATX), for the development and production of theranostic candidates VMT-01 and VMT-α-NET. The radiopharmaceuticals are currently in development for the diagnosis and treatment of metastatic melanoma and neuroendocrine tumors (NETs), respectively.

Perspective Therapeutics and PharmaLogic announce collaboration for the development and production of theranostics for cancer care

News for Perspective Therapeutics Inc Stock (CATX)